The GEO Group (GEO) Q4 2024 earnings summary

Executive summary

• FY 2024 revenue was $2.42 billion, nearly flat year-over-year, with Q4 2024 revenue at $608 million; net income for FY 2024 was $32 million, down from $107.3 million in FY 2023.

• Adjusted EBITDA for FY 2024 was $463.5 million, down from $507.2 million in FY 2023; Q4 2024 Adjusted EBITDA was $108 million, down from $129 million in Q4 2023.

• Q4 and FY 2024 results were impacted by higher G&A expenses, management reorganization, and professional fees in anticipation of 2025 growth.

• Awarded a 15-year, $1 billion ICE contract for Delaney Hall, expected to generate over $60 million in annualized revenue, with full activation in H2 2025.

• GEO operates 99 facilities with about 79,000 beds globally, maintaining a diversified portfolio and high customer retention rates.

Financial highlights

• Q4 2024 net income was $15.5 million ($0.11 per diluted share), down from $25.2 million ($0.17 per share) in Q4 2023.

• Adjusted Q4 2024 net income was $18 million ($0.13 per share), versus $37 million ($0.29 per share) in Q4 2023; full year adjusted net income was $101 million ($0.75 per share).

• Gross margin for FY 2024 was $649.2 million; operating income was $310 million, down from $352.4 million in FY 2023.

• Operating expenses rose 1% year-over-year in Q4, with G&A up 18% due to reorganization and growth preparation.

• Net debt at year-end 2024 was $1.7 billion, with $77 million cash and $214 million liquidity.

Outlook and guidance

• 2025 guidance: net income of $0.74–$0.88 per share, revenue of ~$2.5 billion, adjusted EBITDA of $460–$485 million, and a 28% effective tax rate.

• Net debt reduction of $150–$175 million expected in 2025, with net leverage targeted at 3.1–3.4x.

• Capital expenditures for 2025 projected at $125–$145 million, including $70 million for ICE services expansion.

• Guidance excludes new, unannounced contract awards; upside potential of $800 million–$1 billion in incremental annualized revenue and $250–$300 million in adjusted EBITDA if new opportunities materialize.

• Guidance does not include startup costs for new facilities due to timing uncertainty.